References
- Rubinstein E, Keller N. Future prospects and therapeutic potential of Streptogramin. Drugs 1996; 1 (51 Suppl): 38–42.
- Berthaud N, Desnottes JF. In-vitro bactericidal activity of quinopristin/dalfopristin against adherent Staphylococccus aureus. J Antimicrob Chemother 1997; 39 (Suppl A): 99–102.
- Lamb HM, Figgitt DP, Faulds D. Quinopristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999; 58: 1061–97.
- Jonson AP, Livermore DM. Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal. Lancet 1999; 354: 2012–3.
- Barry AL, Fuchs PC, Brown SD. Susceptibility to RPR 106,972, quinopristin/dalfopristin and erythromicin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres. J Antimicrob Chemother 1998; 42: 651–5.
- Delgado G Jr, Neuhauser MM, Bearden DT, Danziger LH. Quinopristin-dalfopristin: an overview. Pharmacotherapy 2000; 20: 1469–85.
- Kang SL, Rybak MJ. In vitro bacterial activity of quinopristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39 (Suppl A): 33–9.
- Finch RG. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 1996; 1 (51 Suppl): 31–7.
- Lorian V, Fernanades F. Synergistic activity of injectable streptogramin RP590500-vancomycin combination. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17–20 September 1995, San Francisco, CA (abstract no. E126).
- Khurshid MA, Chou T, Charey R, Larsen R, Conover C, Bornstein SL. Staphylococcus aureus with reduced susceptibility to vancomycin—Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000; 48: 1165–7.
- Moellering RC Jr. Staphylococci vs. glycopeptide: How much are the battle lines changing? Clin Infect Dis 1999; 29: 768–70.
- Sambatakou H, Giamarellos Bourboulis EJ, Grecka P, Chrussouli Z, Giamarellou H. In-vitro activity and killing effect of quinopristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interaction with rifampicin and ciprofloxacin against methicillin-resistant isolates. J Antimicrob Chemother 1998; 41: 349–55.